IMU Biosciences closes oversubscribed $53M Series A for immune profiling platform

IMU Biosciences, a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose and treat disease, has successfully brought its Series A to over $53 million (£40 million) in an oversubscribed financing round, co-led by IQ Capital and Molten Ventures, an...